Novo Nordisk’s decision to discontinue Levemir insulin has sparked concerns among Democratic senators. Despite initial praise for Novo’s acquisition of up to 75% of the insulin market, the discontinuation has led to supply disruptions and insurance cutoffs, leaving patients with limited options.